We were blind – Special Invitation from Paul Simms Share FacebookTwitterPinterestWhatsAppLinkedinEmailPrint First Name * Email * Last Name * Company * Country * Lists 02_NEWSLETTER: ANNOUNCEMENTS 02_NEWSLETTER: EDITOR´S PICK 02_NEWSLETTER: FEATURED ARTICLE 02_NEWSLETTER: INDUSTRY NEWS 02_NEWSLETTER: LOOK WHO IS ON THE 03_NEWSLETTER: NATALIE YEADON 02_NEWSLETTER: REGULATORY AFFAIRS Recent Articles Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary... Regulatory Affairs September 27, 2022 Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke Industry News September 27, 2022 Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD Industry News September 27, 2022 DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO Regulatory Affairs September 27, 2022 Bio-Thera Solutions Announces Enrollment Completed in Phase 1 Study for BAT2022, a Broadly Potent Neutralizing Bi-specific Antibody Against SARS-CoV-2 Industry News September 27, 2022 Sign in / Join
